Pl(A1/A2) polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis

被引:309
作者
Ridker, PM
Hennekens, CH
Schmitz, C
Stampfer, MJ
Lindpaintner, K
机构
[1] BRIGHAM & WOMENS HOSP, DIV CARDIOVASC DIS, BOSTON, MA 02115 USA
[2] BRIGHAM & WOMENS HOSP, CHANNING LAB, DEPT MED, BOSTON, MA 02115 USA
[3] HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA USA
[4] HARVARD UNIV, SCH MED, CHILDRENS HOSP, DEPT CARDIOL, BOSTON, MA USA
[5] HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA
[6] HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA
[7] HARVARD UNIV, SCH PUBL HLTH, DEPT BIOL SCI, BOSTON, MA 02115 USA
关键词
D O I
10.1016/S0140-6736(97)80010-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The gene encoding the platelet glycoprotein I[la receptor (GPIIIa), shows polymorphism (P-A1/A2. In a previous study, men with acute coronary ischaemia were more likely than controls to carry the P/(A2) allele. This receptor has an important role in acute thrombus formation; these findings therefore raise the possibility of inherited platelet risk factors for both arterial and venous thrombosis. We investigated whether the P/(A2) allele is associated with myocardial infarction, stroke, and Venous thrombosis in a large prospective cohort of men in the USA. Methods 14916 initially healthy men participating in the Physicians' Health Study provided baseline blood specimens for DNA analysis and were followed prospectively for a mean of 8.6 years. 374 men had a first myocardial infarction, 209 stroke, and 121 venous thrombosis during follow-up (704 cases). Distribution of the P/(A1/A2) polymorphism was investigated by a PCR based on restriction-fragment length polymorphism in these men and in a sample of 704 matched study participants who remained free of thrombosis during follow-up (controls). Findings The frequency of the P/(A2) allele was similar to the control frequency (14.8%) among men who had myocardial infarction (13.5%, p=0.4), stroke (13.4%, p=0.5), or Venous thrombosis (14.5%, p=0.9). The relative risk of any Vascular event among men homozygous or heterozygous for P/(A2) compared with men homozygous for P/(A1) was 0.96 (95% CI 0.8-1.2). We found no evidence of association between the P/(A2) allele and myocardia[ infarction (relative risk 0.93 [95 0.7-1.2]), stroke (0.93 [0.7-1.3]), or venous thrombosis (1.07 [0.7-1.6]). There was no evidence of association in subgroup analyses by age, smoking status, and presence of family history of premature coronary disease, hypercholesterolaemia, hypertension, or diabetes. Aspirin use had no effect on these findings. Interpretation In a large cohort of apparently healthy men, carriage of the GPIIIa P/(A2) allele was not associated with any increase in subsequent risk of myocardial infarction, stroke, or Venous thrombosis.
引用
收藏
页码:385 / 388
页数:4
相关论文
共 17 条
[1]   NOMENCLATURE OF PLATELET-SPECIFIC ANTIGENS [J].
BORNE, AEGV ;
DECARY, F .
TRANSFUSION, 1990, 30 (05) :477-477
[2]   USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY [J].
CALIFF, RM ;
SHADOFF, N ;
VALETT, N ;
BATES, E ;
GALEANA, A ;
KNOPF, W ;
SHAFTEL, J ;
BENDER, MJ ;
AVERSANO, T ;
RAQUENO, J ;
GURBEL, P ;
COWFER, J ;
COHEN, M ;
CROSS, P ;
BITTL, J ;
EDDINGS, K ;
TAYLOR, M ;
DEROSA, K ;
HATTEL, L ;
COOPER, L ;
ESHELMAN, B ;
FINTEL, D ;
NIEMYSKI, P ;
KLEIN, L ;
KENNEDY, H ;
THORNTON, T ;
KEREIAKES, D ;
MARTIN, L ;
ANDERSON, L ;
HIGBY, N ;
ELLIS, S ;
BREZINA, K ;
GEORGE, B ;
CHAPEKIS, A ;
SMITH, D ;
ANWAR, A ;
GERBER, TL ;
PRITCHARD, GL ;
MYLER, R ;
SHAW, R ;
MURPHY, M ;
WARD, K ;
MADIGAN, NP ;
BLANKENSHIP, J ;
HALBERT, M ;
FLANAGAN, C ;
TANNENBAUM, M ;
POLICH, M ;
STEVENSON, C ;
TCHENG, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) :956-961
[3]   BLOCKADE OF PLATELET GPIIB/IIIA RECEPTORS AS AN ANTITHROMBOTIC STRATEGY [J].
COLLER, BS .
CIRCULATION, 1995, 92 (09) :2373-2380
[4]   FINAL REPORT ON THE ASPIRIN COMPONENT OF THE ONGOING PHYSICIANS HEALTH STUDY [J].
HENNEKENS, CH .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (03) :129-135
[5]  
JIN Y, 1993, BLOOD, V82, P2281
[6]   Profound Inhibition of Platelet Aggregation With Monoclonal Antibody 7E3 Fab After Thrombolytic Therapy Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study [J].
Kleiman, Neal S. ;
Ohman, E. Magnus ;
Califf, Robert M. ;
George, Barry S. ;
Kereiakes, Dean ;
Aguirre, Frank V. ;
Weisman, Harlan ;
Schaible, Thomas ;
Topol, Eric J. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1993, 22 (02) :381-389
[7]   MECHANISMS OF DISEASE - PLATELET GLYCOPROTEIN IIB/IIIA RECEPTORS IN CARDIOVASCULAR MEDICINE [J].
LEFKOVITS, J ;
PLOW, EF ;
TOPOL, EJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (23) :1553-1559
[8]   THE HUMAN-PLATELET ALLOANTIGENS, PIA1 AND PIA2, ARE ASSOCIATED WITH A LEUCINE-33 PROLINE-33 AMINO-ACID POLYMORPHISM IN MEMBRANE GLYCOPROTEIN IIIA, AND ARE DISTINGUISHABLE BY DNA TYPING [J].
NEWMAN, PJ ;
DERBES, RS ;
ASTER, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 83 (05) :1778-1781
[9]  
OHMAN EM, 1994, CIRCULATION, V90, P564
[10]   MUTATION IN THE GENE CODING FOR COAGULATION-FACTOR-V AND THE RISK OF MYOCARDIAL-INFARCTION, STROKE, AND VENOUS THROMBOSIS IN APPARENTLY HEALTHY-MEN [J].
RIDKER, PM ;
HENNEKENS, CH ;
LINDPAINTER, K ;
STAMPFER, MJ ;
EISENBERG, PR ;
MILETICH, JP .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (14) :912-917